Polaris Group Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Steve Hsu

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.0003%
Management average tenure	less than a year
Board average tenure	no data

Recent management updates

Recent updates

CEO

Steve Hsu

less than a year

Tenure

Dr. Steve J.P. Hsu serves as Director of DesigneRx Pharmaceuticals, Inc. since May 14, 2024. He is Director of Polaris Pharmaceuticals, Inc. from May 14, 2024.Dr. Steve J.P. Hsu serves as Chairman and Chi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steve Hsu	Chief Executive Officer	less than a year	no data	0.00027% NT$ 105.5k
Jack Fitzgibbons	President	no data	no data	no data
Ray Wu	Chief Financial Officer	less than a year	no data	no data
Chien-Hsing Chang	Chief Strategy Officer	1.4yrs	no data	no data
Kevin Wu	Chief Information Security Officer	less than a year	no data	no data

0.9yrs

Average Tenure

Experienced Management: 6550's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Polaris Group Management

Management criteria checks 0/4

Key information

Recent management updates

Polaris Group Announces the Cancellation of Position of COO of Hui-Yuan Yu

Polaris Group Announces CFO Changes

Polaris Group Announces Change of the Member of Compensation Committee

Polaris Group Announces the Appointment of K Evin Wu

Less than half of directors are independent

Polaris Group Appoints K.C. Tsai as Compensation Committee Member

Recent updates

Third quarter 2024 earnings released: NT$0.96 loss per share (vs NT$0.57 loss in 3Q 2023)

Polaris Group to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings released: NT$0.74 loss per share (vs NT$0.45 loss in 2Q 2023)

IIH Strategic GP, Inc. Issues Pay Warrant to Polaris Group, It Has Now Withdrawn the Lawsuit on Its Own

Polaris Group has filed a Follow-on Equity Offering.

Polaris Group to Report Q2, 2024 Results on Aug 22, 2024

Polaris Group Announces the Cancellation of Position of COO of Hui-Yuan Yu

Polaris Group Announces CFO Changes

New minor risk - Financial data availability

Polaris Group Announces Change of the Member of Compensation Committee

Polaris Group to Report Q1, 2024 Results on May 14, 2024

Polaris Group Announces the Appointment of K Evin Wu

Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20 in Phase II Clinical Trial for NASH at Chang Gung Memorial Hospital, Linkou, Taiwan

Less than half of directors are independent

Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

Polaris Group Appoints K.C. Tsai as Compensation Committee Member

Polaris Group Announces Resignation of TAI, JANG-HUEI as Audit Committee and Remuneration Committee Member

Polaris Group Announces of Resignation of TAI, JANG-HUEI as Independent Director

Polaris Group Announces Dosing of First Patient in Phase 2 Trial of ADI-PEG 20 with Radiation and TMZ in Patients with GBM

Polaris Group Announces MFDS Approves Phase Phase 2 Clinical Protocol Treating GBM with ADI-PEG 20

Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023

Polaris Group Announces that TFDA Approves Phase3 Clinical Protocol Treatment HCC with ADI-PEG 20

Polaris Group Submits ADI-PEG 20 to TFDA for INR as Treatment for Hepatocellular Carcinoma

Polaris Group Receives Pre-BLA Meeting Notice from US FDA for ADI-PEG 20

Polaris Group Receives IND Approval from US FDA for the Investigational New Drug of ADI-PEG 20 to Treat Soft Tissue Sarcoma

Polaris Group Submits ADI-PEG 20 to FDA for IND as A Treatment for Soft Tissue Sarcoma

Third quarter 2022 earnings released: NT$0.41 loss per share (vs NT$0.27 loss in 3Q 2021)

TFDA Approves Polaris Group's Submitted Protocol Amendment of POLARIS2020-001 Phase2 Trial of ADI-PEG 20

Polaris Group Announces CEO Changes

Polaris Group Submits Protocol Amendment of POLARIS2020-001 Phase1-2Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma Multiforme to FDA

Polaris Group Announces Top-Line Efficacy and Safety Data from Phase 3 ATOMIC Study

Polaris Group Appoints Kay Huang as Corporate Governance Officer

Polaris Group Announces Initiation of Phase 3 Clinical Trials of Hepatocellular Carcinoma

New 90-day high: NT$17.70

New 90-day low: NT$15.75

New 90-day low: NT$14.95

CEO

Tenure

Leadership Team

Average Tenure